Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Advances and Perspectives in Cancer Diagnostics and Treatment
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances and Perspectives in Cancer Diagnostics and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 30 January 2026 | Viewed by 1484

Special Issue Editors

Dr. Alexandru E. Eniu

E-Mail Website
Guest Editor
1. Genolier Cancer Center, Clinique de Genolier, 1272 Genolier, Switzerland
2. European School of Oncology, 6 6500 Bellinzona, Switzerland
Interests: breast cancer; global health policy; value-based care; BRCA mutations; BRCA1 mutations; BRCA2 mutations; brca1/2 mutations
Dr. Cristina Marinela Oprean

E-Mail Website
Guest Editor
1. ANAPATMOL Research Center, ‘Victor Babes’ University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania
2. Department of Oncology, ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania
3. Department of Oncology, ONCOMED Outpatient Unit, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania
Interests: breast cancer diagnostic and treatment; imunotherapy; surgery; clinical oncology; psycho-oncology; GI cancer; GU cancer; malign melanoma; oncology education; health promotion; cancer biomarkers; genetic in oncology; RWD
Dr. Simona Ruxandra Volovat

E-Mail Website
Guest Editor
Department of Medical Oncology-Radiotherapy, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Str, 700115 Iasi, Romania
Interests: clinical oncology; medical oncology; cancer biology; health education and promotion; cancer diagnostics; metastasis; cancer biomarkers; molecular oncology; tumor biology; oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As the Guest Editors of the upcoming Special Issue of JCM titled “Advances and Perspectives in Cancer Diagnostics and Treatment”, I am pleased to invite you to contribute a high-quality original research article, comprehensive review, or other paper. This Special Issue aims to highlight the latest developments, innovative methodologies, and future directions in cancer diagnostics and therapeutic strategies.

Given your significant contributions to the field and your recent work on cancer diagnostics and treatment, we believe your expertise would be a valuable addition to this Special Issue.

Key topics of interest include (but are not limited to) the following:

  • Molecular and imaging-based diagnostics.
  • Biomarkers for early detection and prognosis.
  • Advances in targeted therapy and immunotherapy.
  • Artificial intelligence and precision medicine in oncology.
  • Translational research and clinical applications.
  • Clinical–pathological and genetic factors.
  • RWD.
  • Radiotherapy.
  • Prevention in cancer care.

This Special Issue aims to enhance our knowledge regarding the latest advancements in the fields of cancer diagnosis and prognosis. We look forward to receiving your valuable submissions. 

Dr. Alexandru E. Eniu
Dr. Cristina Marinela Oprean
Dr. Simona Ruxandra Volovat
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • solid tumors
  • new advances
  • diagnostics and treatment
  • clinical–pathological
  • genetic factors
  • AI
  • RWD
  • radiotherapy
  • biomarkers
  • prevention in cancer care
  • target therapy
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 816 KiB  
Article
Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality of Bladder Cancer Patients Undergoing Radical Cystectomy
by Daniel-Vasile Dulf, Anamaria Larisa Burnar, Patricia-Lorena Dulf, Doina-Ramona Matei, Hendea Raluca Maria, Cătălina Bungărdean, Maximilian Buzoianu, Iulia Andraș, Tudor-Eliade Ciuleanu, Nicolae Crișan and Camelia Alexandra Coadă
J. Clin. Med. 2025, 14(16), 5810; https://doi.org/10.3390/jcm14165810 - 16 Aug 2025
Viewed by 343
Abstract
Background: Perioperative factors significantly impact oncologic outcomes after radical cystectomy (RC) for bladder cancer. This study aimed to identify key perioperative predictors for overall (OS) and progression-free survival (PFS) and to develop a prognostic nomogram for the identification of high-risk patients adapted to [...] Read more.
Background: Perioperative factors significantly impact oncologic outcomes after radical cystectomy (RC) for bladder cancer. This study aimed to identify key perioperative predictors for overall (OS) and progression-free survival (PFS) and to develop a prognostic nomogram for the identification of high-risk patients adapted to the clinical routines and standard of care of our country. Methods: We retrospectively analyzed 121 patients undergoing RC (2014–2024). Data on patient demographics, comorbidities, tumor pathology, neoadjuvant treatments, extensive intraoperative factors, and postoperative events were assessed using COX models. A prognostic nomogram for 3-year OS was constructed. Results: Median follow-up was 44.33 months. Significant predictors for worse OS included lymphovascular invasion (LVI) (HR 2.22), higher T stage (HR 8.75), N+ status (HR 1.10), and intraoperative complications (HR 3.04). Similar predictors were noted for PFS. The developed nomogram incorporated T-, N-stages, sex, grade, intraoperative complications and early (12 months) recurrence, and was able to significantly identify patients with a higher mortality risk (p < 0.001) with a C-index of 0.74. Conclusions: Our nomogram for mortality prediction of BC patients offers a promising tool for individualized risk stratification. Further studies are required for its external validation. Full article
(This article belongs to the Special Issue Advances and Perspectives in Cancer Diagnostics and Treatment)
►▼ Show Figures

Graphical abstract

14 pages, 480 KiB  
Article
Decoding Treatment Failures in Metastatic Renal Cell Carcinoma: Predictors Across Immunotherapy and Targeted Therapies from a Retrospective Real-World Analysis
by Sorin Saftescu, Vlad-Norin Vornicu, Dorel-Ionel Popovici, Radu-Dumitru Dragomir, Dana-Sonia Nagy, Daniela-Lidia Sandu, Ana Dulan, Șerban-Mircea Negru and Alina-Gabriela Negru
J. Clin. Med. 2025, 14(15), 5271; https://doi.org/10.3390/jcm14155271 - 25 Jul 2025
Viewed by 340
Abstract
Background: Despite recent advances in the management of metastatic renal cell carcinoma (mRCC), real-world outcomes remain heterogeneous, and early treatment failure is common. Predictive biomarkers for time to treatment failure (TTF) outside clinical trials are poorly characterized. Objective: To identify clinical [...] Read more.
Background: Despite recent advances in the management of metastatic renal cell carcinoma (mRCC), real-world outcomes remain heterogeneous, and early treatment failure is common. Predictive biomarkers for time to treatment failure (TTF) outside clinical trials are poorly characterized. Objective: To identify clinical and laboratory predictors associated with early treatment failure in a real-world cohort of mRCC patients treated with immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), or combination regimens. Methods: We conducted a retrospective, single-center analysis of patients with metastatic non-urothelial RCC treated between 2018 and 2023. Cox proportional hazards regression was used to evaluate the association between baseline biological parameters and TTF for each treatment regimen. Results: Among 137 patients receiving first-line therapy, 50 received Ipilimumab + Nivolumab, 49 Sunitinib, and 17 Avelumab + Axitinib. For Ipilimumab + Nivolumab, elevated AST was significantly associated with shorter TTF. For Avelumab + Axitinib, shorter TTF was associated with lymph node metastases, low lymphocyte count, low creatinine, low BMI, and low hemoglobin. For Cabozantinib in subsequent lines, a higher platelet count, ALT, and presence of liver metastases were associated with shorter TTF. No statistically significant predictors were found for Nivolumab used in the second-line setting. Conclusions: Routine, accessible biomarkers such as AST, hemoglobin, lymphocyte count, and creatinine may serve as predictors of treatment failure in specific therapeutic contexts. These findings support risk-adapted strategies and individualized monitoring in real-world clinical practice, though further validation in larger cohorts is warranted. Full article
(This article belongs to the Special Issue Advances and Perspectives in Cancer Diagnostics and Treatment)
►▼ Show Figures

Figure 1

15 pages, 1398 KiB  
Article
Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy
by Daniel-Vasile Dulf, Anamaria Larisa Burnar, Patricia-Lorena Dulf, Doina-Ramona Matei, Raluca Maria Hendea, Iulia Andraș, Miruna Grecea, Cătălina Bungărdean, Antonio De Leo, Tudor-Eliade Ciuleanu, Nicolae Crișan and Camelia Alexandra Coada
J. Clin. Med. 2025, 14(14), 5120; https://doi.org/10.3390/jcm14145120 - 18 Jul 2025
Viewed by 426
Abstract
Background/Objectives: Lymphovascular invasion (LVI) has been consistently linked to poor outcomes in patients with bladder cancer (BC), yet its independent prognostic value, especially after adjusting for established pathological features, remains debated. This study aimed to evaluate the prognostic value of LVI in the [...] Read more.
Background/Objectives: Lymphovascular invasion (LVI) has been consistently linked to poor outcomes in patients with bladder cancer (BC), yet its independent prognostic value, especially after adjusting for established pathological features, remains debated. This study aimed to evaluate the prognostic value of LVI in the context of other pathological features of patients undergoing radical cystectomy. Methods: We conducted a retrospective cohort study including 200 patients treated at the Municipal Clinical Hospital in Cluj-Napoca, Romania. Associations between LVI and overall survival (OS) were assessed using univariable and multivariable Cox proportional hazards models, with Kaplan–Meier curves used for visualizing survival distributions. Results: In univariable analysis, increasing age, presence of LVI, advanced pathological tumor stage (pT ≥ 2), and nodal involvement (pN ≥ 1) were significantly associated with worse OS. LVI was a strong predictor of poor survival (HR 3.13; 95% CI: 2.09; 4.69; p < 0.001). However, in multivariable analysis, only tumor stage (HR 4.85; 95% CI: 2.19; 10.77; p < 0.001) and nodal involvement (HR 1.87; 95% CI: 1.13; 3.09; p = 0.015) remained independently associated with OS. In patients with incomplete nodal staging (Nx), LVI was significantly associated with OS (p = 0.028). Conclusions: Our findings reinforce the prognostic relevance of LVI in bladder cancer and support its role as a marker of aggressive tumor biology, highlighting its value in clinical risk assessment, especially in patients with incomplete nodal staging. Routine reporting of LVI in pathology and consideration in treatment planning are warranted. Full article
(This article belongs to the Special Issue Advances and Perspectives in Cancer Diagnostics and Treatment)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop